Credit Suisse shares plunged Monday after Swiss authorities cut a deal with its bigger rival UBS to acquire the troubled bank at a marked-down price. But European bank stocks and the wider market gained as investors watch whether moves to shore up banks will stem further upheaval in the global finan....
‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 
Unsubscribe
The Early Bird Newsletter
The Early Bird Newsletter

Friday, March 31st

Good Morning

Equity markets moved on Thursday, but it may be another top in a frothy market. The latest rally is driven by hopes the banking crisis is already behind us despite the fact the FOMC is on track to hike rates 1 more time this year. The risk for traders is that PCE data release will be hot or hotter than expected and keep the Fed hiking until later in the year.

If the market can not move higher today, it will confirm resistance for the 3rd time this year. Such a move would keep the S&P 500 rage bound until the 2nd half, when there is an expectation for earnings growth. Until then, investors should stick to their investment plans and use market dips to load up on their favorite stocks.

Featured: Don't Miss Out On These EPIC Profit Stocks (Darwin)

bolt

Markets

Credit Suisse-UBS deal offers hope, but bank doubts persist

Credit Suisse shares plunged Monday after Swiss authorities cut a deal with its bigger rival UBS to acquire the troubled bank at a marked-down price. But European bank stocks and the wider market gained as investors watch whether moves to shore up banks will stem further upheaval in the global finan...

Read the Full Story

From Our Partners

Debunked: One Of Wall Street's Biggest Myths!

Finally released to the public, trading guru Dave Aquino's guide, "The Options Trading Accelerator Method", reveals how Wall Street's big lie has stopped traders with small accounts from reaching their full potential and how his student favorite trading method could change that!

Click here to keep reading…

Markets

Will the Credit Suisse bank takeover calm financial fears?

In a bid to ease turmoil in the world financial system, Swiss authorities engineered a plan for the UBS bank to acquire its troubled smaller rival Credit Suisse at a marked-down price.It's another urgent attempt to fight fears that have put the financial world on edge 15 years after the failure of U...

Read the Full Story

Markets

Is SoFi Technologies a Buy in the Midst of a Banking Crisis?

Every investor knows that “let the buyer beware” is always sound advice. And when you throw in a global banking crisis, that should make investors very cautious. In the midst of this, it can be easy to overlook a small-cap stock like SoFi Technologies, Inc. (NASDAQ: SOFI). The company ...

Read the Full Story

From Our Partners

Biden's corruption knows no end

Porter Stansberry here -- I reveal the shocking changes this Obama policy will usher in… what it means for you, your family, and your finances… and how you can prepare for this new American era.

Stream my new documentary at no cost today.

Click here now - and watch it before it is removed

Markets

Is The Bottom In For RH, Or Is This Just A Stopping Point? 

Signs within the RH (NYSE: RH) report indicate that a bottom could be in play for the stock. While results are worse than the Marketbeat.com consensus figures and the guidance is poor, there is an expectation for margin improvement throughout the year. The company is doubling-down on restructuring...

Read the Full Story

Markets

Put High-Yield Paychex, Inc. On Your Watchlist 

Paychex, Inc. (NASDAQ: PAYX) isn’t a value stock but offers value and yield to investors. Trading at 27X its earnings, it is fairly valued compared to peer Automatic Data Processing (NYSE: ADP) and pays a significantly higher yield. The stock delivers a 2.75% yield, with shares trading near ...

Read the Full Story

From Our Partners

Free Stock Analysis Report: See the Right Way to Analyze Stocks

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

Analyze Any Stock Free

Markets

Bank failures and rescue test Yellen's decades of experience

Working against the clock to stop a developing banking crisis, Treasury Secretary Janet Yellen had until sunset on Sunday, March 12, to come up with a plan to calm the U.S. economy. She quickly turned to someone who had been through the fire before, and on a much larger scale: Hank Paulson. Paulson,...

Read the Full Story

Markets

The Squeeze Is On For EVGo, Rally To Follow 

If you’ve been watching the short interest in EVGo (NYSE: EVGO) and wondering when and if a squeeze will happen, it is. The company’s q4 results and outlook affirm the business potential and have the stock up 25%. That is a significant move driven by short-covering that confirms suppor...

Read the Full Story

Markets

Dividend King H.B. Fuller Signals Slowing In 2023 

Dividend King H.B. Fuller (NYSE: FUL) is not an exciting stock but can be a telling indicator of economic activity. The company makes glue and adhesives for all end market uses, a leading input for all industries. The company’s results don’t point to dividend cuts or suspensions but su...

Read the Full Story

Markets

Silicon Valley Bank collapse concerns founders of color

While Wall Street works to contain the biggest American bank failure since the 2008 financial meltdown, founders of startups who are people of color worry it could become even harder to secure financial support

Read the Full Story

Stocks

After two historic US bank failures, here’s what comes next

Two large banks that cater to the tech industry have collapsed after a bank run, government agencies are taking emergency measures to backstop the financial system, and President Joe Biden is reassuring Americans that the money they have in banks is safe

Read the Full Story

Friday's Early Bird Stock Of The Day

A Stock With Insider Buying:89bio (NASDAQ:ETNB)

89bio

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

View Today's Stock Pick

The Early Bird is a daily email newsletter powered by MarketBeat that covers the top stories that will impact the stock market each day. Read your copy every morning at 7:00 AM Eastern so that you can "catch the worm" when the market opens.

The Early Bird Newsletter
The Early Bird Newsletter

 
MarketBeat Media, LLC
345 N Reid Place, Suite 620, Sioux Falls, SD 57103.
[email protected]
 
Unsubscribe
 
 
Today's Bonus Content: BREAKING: Tiny biotech successfully treats blindness